Charles Lee, PhD
Dr. Charles Lee earned his PhD in Pharmaceutical Chemistry/Pharmacokinetics at the University of California, San Francisco, and his MS degree in Physical Chemistry at Auburn University in Auburn, Alabama.
Over the course of thirty years in pharmaceutical sciences, Dr. Charles Lee has served in numerous industry and academic positions, including his recent tenure as Professor of Pharmaceutical Sciences at the Gregory School of Pharmacy, Palm Beach Atlantic University. Previously, Dr. Lee served as Assistant Professor, University of Florida, College of Pharmacy, and as Associate Professor at the University of Houston, College of Pharmacy.
Dr. Charles Lee is an accomplished researcher with several book chapters to his credit, and publications in peer-reviewed scientific journals such as the Journal of Clinical Pharmacology, Journal of Pharmaceutical Sciences, International Journal of Pharmaceutics, and others.
Dr. Lee has served as an Ad Hoc reviewer for several National Institutes of Health study sections in the United States, and as Advisor, Bureau of Pharmaceutical Affairs, Department of Health, in Taiwan.
An expert in pharmaceutical sciences, Dr. Lee previously served as Director of Pharmacokinetics with NYSE-listed, KV Pharmaceuticals, where among other duties, he coordinated and supervised the preparation of numerous applications to the FDA, including Investigational New Drug, New Drug Application, and Abbreviated New Drug Application submissions. Dr. Charles Lee also served as the company’s liaison to the FDA in the United States, and foreign health authorities in Canada and Japan.
Subsequently, Dr. Charles Lee served as Assistant Director, Clinical Pharmacology at Wyeth Research, one of the world's largest research-driven pharmaceutical and health care products companies. Following his term at Wyeth, Dr. Charles Lee joined Fujisawa Healthcare, a division of Fujisawa Pharmaceuticals (now Astellas), founded in 1894 and ranked among Japan’s top five pharmaceutical companies.
Mark Bossie, PhD
Dr. Bossie received a B.S. degree in Biology from The College of New Jersey (formerly Trenton State), and earned his PhD in Microbiology and Molecular Biology at Rutgers University. Following his graduate studies, Dr. Mark Bossie joined the Molecular Biology Department at Princeton University, where he undertook and completed his post-doctoral research efforts.
Upon completion of his post-doctoral work, Dr. Bossie joined Bristol Myers-Squibb, developers of the world’s most widely used cancer treatment, Taxol®, a naturally-derived pharmaceutical compound.
Subsequently, Dr. Bossie accepted appointment as Senior Research Scientist at the Plant Biotechnology Department at American Cyanamid, and quickly rose to the rank of Group Leader, managing and leading research teams in various projects, including compound discovery.
Dr. Bossie was a central figure in the establishment of American Cyanamid’s most significant ventures into genomics-based discovery and initiatives into the use of plant biotechnology outside of crop protection.
Following the sale of American Cyanamid to BASF, Dr. Bossie accepted appointment as Research Director at Icon Genetics, a biotechnology company engaged in developing novel plant technologies targeted at the production of therapeutic pharmaceuticals in plant-based production systems.
Since the successful sale of Icon Genetics’ US interests, Dr. Mark A. Bossie has provided private consulting in the areas of biotechnology, and scientific and medical communications, working across a wide array of therapeutic disciplines for some of the world’s leading pharmaceutical companies.
Li-Xi Yang, MD, PhD
Dr. Li-Xi Yang has more than 25 years of experience in the fields of cancer research, credited with many patents on anticancer compounds and publications in peer-reviewed journals.
Dr. Yang completed his Postdoctoral Fellowship at Dartmouth Medical School, where he received his PhD in Pharmacology and Toxicology.
He currently serves as Director of Radiation Oncology Residency Education and Senior Scientist at California Pacific Medical Center Research Institute. Dr. Yang also serves as Director of Academic Research at St. Mary’s Medical Center, San Francisco, CA.
Dr. Li-Xi Yang is an active member of several professional committees, including: Graduate Medical Education Committee, Institutional Review Board, and Institutional Animal Care and Use Committee.
|
